Pfizer set for top 10 spot in India as formal Wyeth merger agreed
This article was originally published in Scrip
Almost five years after Pfizer announced its $68bn acquisition of Wyeth globally, the two companies' already operationally "harmonized" India arms have approved plans for a formal legal merger, rewarding shareholders with a pre-merger dividend payout and promising improved long-term value from the combined entity.
You may also be interested in...
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.